foxred2 Antibody

What is FOXRED2 and why is it important in cellular research?

FOXRED2 (FAD-dependent oxidoreductase domain-containing protein 2), also known as ERFAD (Endoplasmic reticulum flavoprotein associated with degradation), is a 684 amino acid protein that functions primarily in the endoplasmic reticulum (ER). It plays a crucial role in the endoplasmic reticulum-associated degradation (ERAD) pathway, binding non-native proteins in the ER and targeting them to the ubiquitination machinery for subsequent degradation .

Research significance:

What applications are FOXRED2 antibodies validated for?

FOXRED2 antibodies have been validated for multiple research applications with varying degrees of optimization:

Methodological recommendation: When establishing a new application, initial optimization with positive control samples (e.g., melanoma cell lines A2058 or A375) is strongly recommended based on their confirmed high FOXRED2 expression .

How should researchers select between polyclonal and monoclonal FOXRED2 antibodies?

Selection should be based on experimental requirements:

Polyclonal FOXRED2 Antibodies:

• Advantages: Recognize multiple epitopes, potentially higher sensitivity for detection of low abundance proteins, better for initial screening experiments

• Applications: Generally preferred for IHC applications where signal amplification is beneficial

• Considerations: Lot-to-lot variability must be accounted for in longitudinal studies

Monoclonal FOXRED2 Antibodies (e.g., B-10):

• Advantages: Consistent reproducibility, higher specificity for a single epitope, reduced background

• Applications: Ideal for applications requiring high specificity such as IP and quantitative analyses

• Considerations: Available with various conjugates (HRP, FITC, PE, Alexa Fluor), enabling multiplexed analyses

Methodological recommendation: For critical experiments requiring precise quantification of FOXRED2 expression changes, monoclonal antibodies provide more consistent results across experimental replicates. For tissue staining where sensitivity is paramount, polyclonal antibodies may yield better results.

How should researchers validate FOXRED2 antibody specificity in their experimental system?

A rigorous validation approach includes:

• Positive controls: Use tissues/cells with known FOXRED2 expression (e.g., neuronal cells, melanoma cell lines A2058 and A375)

• Negative controls: Include conditions where:

  • Primary antibody is omitted

  • Blocking peptide competition is performed with recombinant FOXRED2 protein fragments (e.g., Human FOXRED2 aa 255-404 control fragment)

  • FOXRED2 knockdown samples are used (siRNA approach as described in melanoma studies)

• Cross-reactivity testing: Consider species homology - human FOXRED2 has 85-87% sequence identity with mouse and rat orthologs

• Western blot validation: Confirm antibody detects bands of expected molecular weight (approximately 78 kDa)

Recommended methodological approach: Pre-incubate antibody with a 100x molar excess of protein control fragment for 30 minutes at room temperature before application in blocking experiments to confirm specificity .

What are the optimal fixation and antigen retrieval methods for FOXRED2 immunohistochemistry?

Based on successful FOXRED2 IHC protocols documented in melanoma and neurological studies:

Fixation:

• Formalin fixation (10% neutral buffered formalin) has been validated for paraffin-embedded tissues

• Fixation time of 24-48 hours at room temperature is typically sufficient

• Extended fixation may require more aggressive antigen retrieval

Antigen Retrieval Methods:

• Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is most commonly successful

• For challenging tissues, try EDTA buffer (pH 8.0) as an alternative

• Optimal retrieval time: 20 minutes at 95-98°C

Detection Systems:

• For FOXRED2 IHC, AEC Peroxidase Substrate Kit has been successfully used with red particle deposition in cytoplasm and cell membrane indicating positive results

• Hematoxylin counterstaining provides good nuclear contrast

Practical consideration: When analyzing FOXRED2 expression in cutaneous malignant melanoma (CMM), the positivity rate differences are notable - reported as 0% in normal controls and nevus tissues versus 89.5% in melanoma tissues .

What controls should be included when using FOXRED2 antibodies for quantitative analysis?

For rigorous quantitative analysis:

• Technical controls:

  • Concentration-matched isotype controls (same species, same immunoglobulin class)

  • Gradient dilution series to establish linear detection range

  • Loading controls for normalization (e.g., housekeeping proteins for WB)

• Biological controls:

  • Positive tissue/cell controls (melanoma tissue for high expression, normal skin for low/negative expression)

  • Genetic controls (FOXRED2 knockdown using validated siRNAs):

    • Validated siRNA sequences:

      • si1: FOXRED2-Homo-327 (5′-GCAGCUUCUUCACACGCUATT-3′)

      • si2: FOXRED2-Homo-608 (5′-GGCCACUACUUCAUCCUAATT-3′)

      • si3: FOXRED2-Homo-1090 (5′-GGACGACAAUGACAACUUUTT-3′)

• Quantification approaches:

  • For IHC: Determine staining intensity scoring system (e.g., 0=negative, 1=mild, 2=strong)

  • For WB: Densitometric analysis with appropriate normalization

  • For IF: Mean fluorescence intensity measurements with background subtraction

Methodological note: Research has shown timing discrepancies between mRNA and protein expression levels of FOXRED2, suggesting post-transcriptional regulation. The optimal reaction timing for siRNA transfection and protein expression assessment in A375 and A2058 cells is 48-72h .

How can FOXRED2 antibodies be applied to investigate its role in amyloid β-induced neuronal toxicity?

FOXRED2 has been identified as a mediator of amyloid β (Aβ)-induced neuronal cell death through proteasome inhibition . To investigate this mechanism:

Recommended experimental approach:

• Temporal expression analysis:

  • Expose primary rat cortical neurons or SH-SY5Y cells to Aβ42

  • Perform time-course analysis (0, 6, 12, 24, 48h) of FOXRED2 expression using Western blot

  • FOXRED2 protein shows significant elevation at 24h post-Aβ exposure

• Functional analysis using GFP-degron reporter system:

  • Transfect cells with GFP-CL1 (unstable GFP) and FOXRED2 expression constructs

  • Monitor GFP-CL1 accumulation as indicator of proteasome inhibition

  • Correlation between FOXRED2 expression level and unstable GFP accumulation indicates dose-dependent effects

• Mechanistic investigation:

  • Assess proteasome activities (chymotrypsin, trypsin, and caspase-like) using fluorogenic substrates

  • Monitor ubiquitin-conjugated protein accumulation by Western blot

  • Use Salubrinal to inhibit ER stress-mediated cell death pathway to confirm FOXRED2 mechanism

Key finding: Knockdown of FOXRED2 expression by siRNA results in enhancement of proteasome activity by 140–170% in a dose-dependent manner and abolishes both Aβ42-mediated inhibition of proteasome activity and accumulation of ubiquitin-conjugates .

What are the methodological considerations for studying FOXRED2's role in melanoma progression?

Research has established FOXRED2 as significantly upregulated in cutaneous malignant melanoma with prognostic implications . For investigating its role:

Bioinformatic analysis approach:

• Use GEPIA2 and TIMER databases to assess FOXRED2 expression differences between:

  • Cutaneous malignant melanoma vs. normal controls

  • Primary melanoma vs. metastatic melanoma

  • High vs. low FOXRED2 expression patient cohorts for survival analysis

Tissue analysis methodologies:

• IHC staining using FOXRED2 antibodies (1:200 dilution)

• Scoring system: red particles in cytoplasm/cell membrane indicate positive staining

• Compare positivity rates across:

  • Normal skin (reported 0% positivity)

  • Nevus tissues (reported 0% positivity)

  • Melanoma tissues (reported 89.5% positivity)

Cellular functional studies:

• Cell model selection:

  • A2058 cells (metastatic melanoma line) - show higher FOXRED2 gene expression

  • A375 cells (primary melanoma line) - show differential protein expression patterns

• Functional assays after FOXRED2 knockdown:

  • Proliferation: CCK-8 assay (shows inhibition of cell proliferation)

  • Migration: Scratch-wound healing assay (shows inhibition of migration)

  • Invasion: Transwell assays (shows suppression of cell migration and invasion)

  • Apoptosis: Flow cytometry analysis

Notable finding: Metastatic melanoma A2058 cells showed enhanced attack and metastatic ability compared to primary melanoma A375 cells, but A2058 cells showed significantly reduced invasion and migration ability after FOXRED2 knockdown .

How can protein-protein interaction studies be optimized using FOXRED2 antibodies?

To investigate FOXRED2's interactome:

Co-Immunoprecipitation (Co-IP) optimization:

• Antibody selection:

  • Use monoclonal antibodies (e.g., B-10) conjugated to agarose for direct IP

  • For sequential IP, use unconjugated antibodies with protein A/G beads

• Lysis conditions:

  • For ER-resident proteins like FOXRED2, use mild detergents (0.5-1% NP-40 or CHAPS)

  • Include protease inhibitors and phosphatase inhibitors

  • Maintain physiological pH (7.4) to preserve native interactions

• Cross-linking considerations:

  • For transient interactions, consider reversible crosslinkers like DSP

  • For stable complexes, standard IP without crosslinking may be sufficient

Mass spectrometry identification of interactors:

• Use LC-MS/MS analysis of co-IP samples

• Filter against IgG control samples to remove non-specific binding

• Validate top candidates with reciprocal IPs and Western blotting

Research-based insight: Since FOXRED2 is an unstable protein with two degradation boxes and one KEN box, and its N-terminal oxidoreductase domain is required for proteasome inhibition , interaction studies should consider the stability of different protein domains and their functional significance.

How can researchers address discrepancies between FOXRED2 mRNA and protein expression levels?

Research has documented inconsistencies between FOXRED2 mRNA and protein expression in certain experimental systems . To address this:

Potential causes of mRNA-protein discrepancy:

• Post-transcriptional regulation

• Protein stability variations

• Spatiotemporal differences in expression

• Methodological limitations

Recommended investigation approach:

• Temporal analysis:

  • Perform time-course experiments (24-72h) to capture potential time lags between transcription and translation

  • Optimal reaction timing for assessing siRNA effects on FOXRED2: 48-72h post-transfection

• Protein stability assessment:

  • Use cycloheximide chase experiments to determine FOXRED2 half-life

  • Consider proteasome inhibitors (MG132) to assess degradation pathways

  • Evaluate effects of degradation boxes and KEN box mutations on stability

• Subcellular fractionation:

  • Isolate distinct cellular compartments (cytosol, ER, mitochondria)

  • Compare FOXRED2 distribution across fractions

  • Consider potential translocation mechanisms

Key research observation: In melanoma studies, RT-qPCR experiments indicated higher FOXRED2 expression in A2058 cells than in A375 cells, while Western blot experiments revealed higher FOXRED2 expression in A375 cells compared to A2058 cells, suggesting independent regulation of mRNA and protein levels .

What factors influence FOXRED2 antibody performance in different experimental contexts?

Understanding these factors helps optimize experimental protocols:

Tissue/sample-specific considerations:

• Fixation effects:

  • Over-fixation may mask epitopes

  • Insufficient fixation may compromise tissue morphology

  • Solution: Optimize fixation time and antigen retrieval methods

• Expression level variations:

  • High expression in cutaneous malignant melanoma (89.5% positivity)

  • Low/absent expression in normal skin and nevus tissues (0% positivity)

  • Neural tissues show strong cytoplasmic positivity in neuronal cells

Antibody characteristics:

• Epitope accessibility:

  • N-terminal epitopes (aa 1-200) vs. mid-region epitopes (aa 255-404)

  • Different antibodies target different regions with varying accessibility

• Antibody format effects:

  • Unconjugated vs. conjugated antibodies (HRP, FITC, PE, Alexa Fluor)

  • Different conjugates may affect sensitivity and specificity

Practical approach: When transitioning between experimental systems, perform validation using proven positive controls from the literature (e.g., melanoma cell lines A2058/A375 for high expression, normal skin for negative control) .

How should researchers interpret contradictory findings about FOXRED2 localization?

FOXRED2 has been described as both an ER-resident protein and having mitochondrial associations . To reconcile these findings:

Methodological approach to resolve localization questions:

• Co-localization studies:

  • Use dual immunofluorescence with established markers:

    • ER markers: Calnexin, PDI, KDEL

    • Mitochondrial markers: TOM20, MitoTracker

  • Apply super-resolution microscopy for precise localization

• Biochemical fractionation:

  • Perform careful subcellular fractionation to isolate pure ER and mitochondrial fractions

  • Western blot analysis with fraction-specific markers to confirm purity

  • Quantify FOXRED2 distribution across fractions

• Domain-specific localization:

  • Generate truncation or domain-specific mutants

  • Assess localization of each construct to identify targeting sequences

Research-based insight: FOXRED2's FAD-dependent oxidoreductase domain is critical for its function in proteasome inhibition , while its subcellular localization may influence its role in different cellular contexts. Its relationship to FOXRED1 (which has established mitochondrial functions) suggests potential dual localization or context-dependent trafficking .

How can FOXRED2 antibodies be applied to investigate its potential role in neurodegenerative diseases?

Given FOXRED2's established role in Aβ-induced neuronal toxicity and its expression in hippocampal neurons , several research approaches are warranted:

Methodological approaches:

• Comparative expression analysis:

  • Use FOXRED2 antibodies for IHC/IF on brain tissues from:

    • Alzheimer's disease patients vs. age-matched controls

    • Parkinson's disease models

    • Other proteinopathy models (ALS, Huntington's)

  • Apply quantitative analysis of expression patterns in vulnerable vs. resistant neuronal populations

• Mechanistic investigation:

  • Explore FOXRED2's relationship with proteasome function in neurodegenerative contexts

  • Use neuronal cell models (primary cultures, iPSC-derived neurons) with disease-relevant stressors

  • Perform FOXRED2 knockdown/overexpression to assess impact on:

    • Protein aggregation (Aβ, tau, α-synuclein)

    • ER stress markers

    • Neuronal survival

• In vivo studies:

  • Generate conditional FOXRED2 knockout models

  • Assess impact on neurodegenerative disease progression

  • Use FOXRED2 antibodies for monitoring expression changes during disease progression

Research-based rationale: FOXRED2 knockdown abolishes Aβ42-mediated inhibition of proteasome activity , suggesting it could be a therapeutic target for neurodegenerative diseases involving proteasome dysfunction.

What methodological approaches can reveal the functional significance of FOXRED2 in cancer beyond melanoma?

While FOXRED2's role in melanoma is established , its potential involvement in other cancers requires investigation:

Multi-cancer screening approach:

• Tissue microarray analysis:

  • Use FOXRED2 antibodies to screen TMAs containing multiple cancer types

  • Compare expression levels across cancer types and stages

  • Correlate with clinical outcomes

• Cancer cell line panel characterization:

  • Screen NCI-60 or other cancer cell line panels for FOXRED2 expression

  • Correlate with other -omics data to identify potential associations

  • Select high-expressing lines for functional studies

Functional validation methodology:

• CRISPR-Cas9 knockout studies:

  • Generate FOXRED2 knockout in selected cancer cell lines

  • Assess impact on:

    • Proliferation and survival

    • Migration and invasion

    • Response to therapy

    • In vivo tumor growth

• Mechanism exploration:

  • Investigate FOXRED2's role in proteasome function across cancer types

  • Assess impact on ER stress and unfolded protein response

  • Explore potential correlations with drug resistance mechanisms

Research-based insight: The relationship between FOXRED2 expression and enhanced metastatic ability observed in melanoma suggests it might play similar roles in other aggressive cancers, particularly those with high ER stress or proteasome dependency.

How should researchers approach the investigation of potential FOXRED2 polymorphisms and their clinical significance?

Given FOXRED2's involvement in various pathological conditions, genetic variations may have significant implications:

Recommended methodological workflow:

• Genetic variation identification:

  • Mine existing genome/exome sequencing databases for FOXRED2 variants

  • Focus on:

    • Coding region polymorphisms

    • Variations in regulatory regions

    • Population-specific variants

• Functional characterization:

  • Generate expression constructs with identified variants

  • Assess impact on:

    • Protein stability and localization using FOXRED2 antibodies

    • Interaction with binding partners

    • Effect on proteasome function and ERAD

    • Cell type-specific effects

• Clinical correlation studies:

  • Design targeted genotyping studies for patient cohorts

  • Focus on diseases with established FOXRED2 involvement:

    • Melanoma patients (correlate with prognosis)

    • Neurodegenerative disease cohorts

    • Potential links to mitochondrial disorders (given relationship to FOXRED1)

Research-based insight: FOXRED2 is located on human chromosome 22 , a region associated with several genetic disorders including Phelan-McDermid syndrome and neurofibromatosis type 2. Investigating potential overlaps between FOXRED2 variants and these conditions could reveal new disease mechanisms.

How can advanced imaging techniques be optimized for FOXRED2 visualization and quantification?

Leveraging cutting-edge imaging technologies:

Super-resolution microscopy approaches:

• STED (Stimulated Emission Depletion) microscopy:

  • Optimal for resolving FOXRED2 subcellular localization

  • Compatible with standard immunofluorescence protocols

  • Antibody recommendations: Use directly labeled primary antibodies or high-quality secondary antibodies with minimal background

• STORM/PALM techniques:

  • Requires photoconvertible fluorophore-conjugated antibodies

  • Enables single-molecule localization

  • Best for precise co-localization with other proteins

Live-cell imaging considerations:

• CRISPR knock-in strategies:

  • Generate endogenous FOXRED2-fluorescent protein fusions

  • Validate expression and function matches native protein

  • Use for dynamic studies of FOXRED2 trafficking and turnover

Research-based contextual application: Advanced imaging could help resolve the apparent discrepancies between FOXRED2's reported ER localization and its potential mitochondrial associations .

What are the best methodological approaches for studying FOXRED2 post-translational modifications?

Understanding FOXRED2 regulation through PTMs:

PTM identification workflow:

• Mass spectrometry approach:

  • Immunoprecipitate FOXRED2 using validated antibodies

  • Perform LC-MS/MS analysis focusing on:

    • Ubiquitination sites (given FOXRED2's role in ERAD)

    • Phosphorylation (potential regulatory mechanism)

    • Oxidation states (relevant to FAD-binding domain)

• Site-specific mutant generation:

  • Create point mutations at identified PTM sites

  • Assess impact on:

    • Protein stability and localization

    • FAD binding and oxidoreductase activity

    • Interaction with ERAD machinery

PTM-specific antibody development considerations:

• For confirmed key PTM sites, consider developing PTM-specific antibodies

• Validate specificity using appropriate PTM-negative controls (mutants)

Research-based insight: Given FOXRED2's identification as an unstable protein with two degradation boxes and one KEN box , understanding its ubiquitination patterns may provide crucial insights into its regulation in different cellular contexts.

How can multi-omics approaches incorporating FOXRED2 antibodies advance understanding of its biological functions?

Integrating multiple data types:

Recommended multi-layered approach:

• Proteomics integration:

  • Use FOXRED2 antibodies for immunoprecipitation-mass spectrometry (IP-MS)

  • Identify protein interaction networks in different cellular contexts

  • Compare interactomes between:

    • Normal vs. disease states

    • Different cell/tissue types

    • Wild-type vs. mutant FOXRED2

• ChIP-seq applications:

  • While FOXRED2 is not a transcription factor, its potential involvement in regulatory complexes could be explored

  • Use carefully validated FOXRED2 antibodies for chromatin immunoprecipitation

  • Integrate with transcriptomic data to identify potential regulatory roles

• Spatial omics integration:

  • Apply FOXRED2 antibodies in spatial transcriptomics/proteomics platforms

  • Map FOXRED2 expression patterns in tissue contexts

  • Correlate with local transcriptome/proteome profiles